REGENXBIO Inc. (RGNX) News

REGENXBIO Inc. (RGNX): $24.26

-0.12 (-0.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RGNX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter RGNX News Items

RGNX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RGNX News Highlights

  • RGNX's 30 day story count now stands at 14.
  • Over the past 25 days, the trend for RGNX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DRUG, GENE and KALA are the most mentioned tickers in articles about RGNX.

Latest RGNX News From Around the Web

Below are the latest news stories about REGENXBIO Inc that investors may wish to consider to help them evaluate RGNX as an investment opportunity.

REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, March 1, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021, and recent operational highlights.

Yahoo | February 22, 2022

Protagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock?

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | February 16, 2022

RegenXBio (RGNX) Receives a Hold from Leerink Partners

In a report released yesterday, Mani Foroohar from Leerink Partners maintained a Hold rating on RegenXBio (RGNX – Research Report). The company's shares closed last Tuesday at $26.19, close to its 52-week low of $24.14. According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -18.0% and a 38.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and 4D Molecular Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RegenXBio with a $44.50 average price target, implying a 77.3% upside from current levels.

Catie Powers on TipRanks | February 15, 2022

REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogenesis, Exudation, and Degeneration 2022 conference by Michael A. Klufas, M.D., Retina Service, Wills Eye Hospital, Assistant Professor of Ophthalmology, Thomas Jefferson University.

Yahoo | February 12, 2022

We're Hopeful That REGENXBIO (NASDAQ:RGNX) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | February 11, 2022

RegenXBio (RGNX) Receives a Hold from Wedbush

In a report released today, Andreas Argyrides from Wedbush reiterated a Hold rating on RegenXBio (RGNX – Research Report), with a price target of $29.00. The company's shares closed last Thursday at $25.87, close to its 52-week low of $24.14. According to TipRanks.com, Argyrides is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -32.4% and a 20.0% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Clearside Biomedical, and Unity Biotechnology. RegenXBio has an analyst consensus of Moderate Buy, with a price target consensus of $39.33, implying a 47.4% upside from current levels.

Brian Anderson on TipRanks | February 10, 2022

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022

RGX-111, a potential one-time gene therapy for MPS I, is well-tolerated across two dose levels, with no drug-related serious adverse events

Yahoo | February 9, 2022

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels

Yahoo | February 9, 2022

REGENXBIO Announces Presentations at the 11th Annual SVB Leerink Global Healthcare Conference

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 8:40 a.m. ET. The conference will be held in a virtual meeting format.

Yahoo | February 8, 2022

Wedbush Sticks to Its Hold Rating for RegenXBio (RGNX)

In a report released today, Andreas Argyrides from Wedbush reiterated a Hold rating on RegenXBio (RGNX – Research Report), with a price target of $29.00. The company's shares closed last Monday at $26.99, close to its 52-week low of $24.14. According to TipRanks.com, Argyrides is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -34.1% and a 0.0% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Clearside Biomedical, and Unity Biotechnology. RegenXBio has an analyst consensus of Moderate Buy, with a price target consensus of $41.33, representing a 56.4% upside.

Christine Brown on TipRanks | February 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5295 seconds.